Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Окт. 4, 2024
Objective
The
aim
of
this
study
was
to
characterize
the
phenotype
and
genotype
patients
with
Yao
syndrome
(YAOS),
focus
on
comparing
prior
cohorts,
identifying
novel
features,
describing
treatment
observations.
Methods
A
retrospective
medical
records
review
YAOS
seen
at
Mayo
Clinic
conducted
clinical
NOD2
genotypes,
therapeutic
trials
responses.
Results
Twenty-two
diagnosed
were
included.
Eighteen
(81.8%)
female
twenty
(90.9%)
White.
Mean
age
symptom
onset
24.0
±
14.8
years.
Common
manifestations
included
fever
(81.8%
patients),
rash
(95.5%),
chronic
gastrointestinal
symptoms
(100%),
arthralgia/arthritis
sicca
(68.2%).
genotypes
as
single
variants
IVS8
+
158
in
14
(63.6%),
R702W
8
(36.4%),
1007fs
4
(18.2%),
one
patient
had
only
a
previously
unreported
rare
variant.
Eight
(36.4%)
compound
(two
or
more)
variants.
Potential
comorbidities
observed
cohort
dysmotility,
autonomic
dysfunction,
mast
cell
activation-like
symptoms.
Glucocorticoid
responsiveness
15
20
exposed
(75%).
Eleven
(50.0%)
received
IL-1
inhibitor
therapy,
(4.5%)
IL-6
therapy
adequate
disease
control.
Conclusion
Our
findings
substantiate
occurrence
fevers,
arthralgia/arthritis,
rash,
symptoms,
sicca-like
described
YAOS.
Novel
features
variant
not
identified.
Glucocorticoids,
biologic
inhibitors,
receptor
inhibitors
appeared
be
effective
for
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Янв. 29, 2024
Objective
To
assess
the
impact
conferred
by
NOD2
variants
on
clinical
spectrum
of
patients
with
systemic
autoinflammatory
diseases
(SAIDs)
in
Greece.
Methods
Consecutive
(n=167)
confirmed
SAIDs
who
underwent
screening
next
generation
sequencing
(NGS)
targeting
26
SAID-associated
genes,
and
carried
at
least
one
gene
variant,
were
retrospectively
studied.
The
demographic,
laboratory
parameters
recorded.
Results
In
total,
24
rare
23/167
(14%)
detected.
Notably,
18
had
co-existing
variant
13
genes
other
than
.
Nine
juvenile-
14
adult-onset
disease.
All
presented
symptoms
potentially
induced
variants.
particular,
candidate
diagnosis
was
Yao
syndrome
(YAOS)
12
(7%
whole
SAID
cohort).
YAOS
(mean
episode
duration
8
days)
fever
(n=12/12),
articular
(n=8),
gastrointestinal
(n=7;
abdominal
pain/bloating
7;
diarrhea
4;
oral
ulcers
3),
serositis
(n=7),
rash
(n=5),
while
inflammatory
markers
elevated
all
but
patient.
Most
these
showed
a
poor
response
to
nonsteroidal
anti-inflammatory
drugs
(n=7/9),
colchicine
(n=6/8)
and/or
anti-TNF
treatment
(n=3/4),
complete
observed
6/10
receiving
steroids
3/5
anti-IL1
treatment.
Another
diagnosed
either
FMF
(n=6)
or
PFAPA
(n=2)
presenting
prominent
(n=2),
periorbital
swelling
sicca-like
(n=1),
maculopapular
(n=1).
One
patient
clinically
undefined
SAID,
albeit
characterized
diarrhea.
Finally,
chronic
relapsing
urticaria
edema
markers,
another
Crohn-like
good
anti-IL-1
refractory
Conclusion
detected
1
out
7
seem
have
an
disease
phenotype
response.
Further
studies
should
validate
combined
molecular
data
better
understand
distinct
nosological
entities.
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Окт. 19, 2023
NOD-like
receptors
(NLRs)
are
intracellular
sensors
associated
with
systemic
autoinflammatory
diseases
(SAIDs).
We
investigated
the
largest
monocentric
cohort
of
patients
adult-onset
SAIDs
for
coinheritance
low
frequency
and
rare
mutations
in
NOD2
other
genes.
Sixty-three
underwent
molecular
testing
SAID
gene
panels
after
extensive
clinical
workups.
Whole
exome
sequencing
data
from
large
Atherosclerosis
Risk
Communities
(ARIC)
study
individuals
European-American
ancestry
were
used
as
control.
Of
63
patients,
44
(69.8%)
found
to
carry
combined
variants
another
(Group
1),
19
(30.2%)
carriers
only
2).
The
genetic
variant
combinations
digenic
66%
(NOD2/MEFV,
NOD2/NLRP12,
NOD2/NLRP3,
NOD2/TNFRSF1A)
oligogenic
34%
cases.
These
either
absent
or
significantly
less
frequent
control
population.
By
phenotype-genotype
correlation,
approximately
40%
met
diagnostic
criteria
a
specific
SAID,
60%
had
mixed
diagnoses.
There
no
statistically
significant
differences
manifestations
between
two
patient
groups
except
chest
pain.
Due
overlapping
phenotypes
genotypes,
we
have
suggested
new
term,
"Mixed
NLR-associated
Autoinflammatory
Disease
",
describe
this
disease
scenario.
Gene
primarily
presenting
phenotypes.
Our
support
proposition
that
immunological
expression
is
modified
by
background
environmental
exposure.
provide
preliminary
framework
diagnosis,
management,
interpretation
Genes,
Год журнала:
2025,
Номер
16(4), С. 401 - 401
Опубликована: Март 30, 2025
Genetically
transitional
disease
(GTD)
is
emerging
as
a
new
concept
in
genomic
medicine
to
straddle
between
the
traditional
binary
classification
of
monogenic
and
polygenic
disease.
Genetic
testing
result
reports
molecular
laboratories
have
been
predicated
on
model,
which
focuses
pathogenic
likely
variants.
While
variants
uncertain
significance
(VUS)
are
reported
by
laboratories,
there
challenges
with
regard
their
clinical
application
so
that
these
often
dismissed
ordering
physicians.
Unlike
Mendelian
disorders,
where
genetic
high
penetrance
highly
probabilistic,
GTD
employed
highlight
impact
low-to-moderate
effect
gene
whose
influence
modified
background.
The
may
explain
health
conditions
associated
necessary
but
not
sufficient
for
pathogenesis,
lying
mid
gray
zone
diseases.
Although
VUSs
reach
level
pathogenicity
based
American
College
Medical
Genetics
Genomics
guidelines,
they
could
be
provisionally
classified
GTD-associated
annotate
interpret
relationship
VUS
human
appropriate
implementation
patient
care
research
focusing
attention
individual
variability
responses
various
Frontiers in Immunology,
Год журнала:
2024,
Номер
14
Опубликована: Янв. 26, 2024
Objectives
Cryopyrin-associated
periodic
syndrome
or
NLRP3-associated
autoinflammatory
disease
(NLRP3-AID)
and
NLRP12-AID
are
both
Mendelian
disorders
with
autosomal
dominant
inheritance.
Both
diseases
rare,
primarily
reported
in
the
pediatric
population,
thought
to
be
phenotypically
indistinguishable.
We
provide
largest
cohort
of
adult-onset
patients
compared
these
gene
variant
frequency
population
controls.
Methods
A
adult
AIDs
were
retrospectively
studied.
All
underwent
molecular
testing
for
fever
panels
after
extensive
negative
workups
systemic
autoimmune
other
related
diseases.
Patients
divided
into
Group
1-
NLRP3-AID
NLRP3
variants
(N=15),
2-
NLRP12
(N=14)
3-
(N=9)
variants.
Exome
sequence
data
two
large
control
populations
including
ARIC
study
used
compare
distribution
frequency.
Results
38
Caucasian
women
accounting
82%.
Median
age
at
diagnosis
was
41
±
23
years
duration
14
13
years.
identified
statistically
significant
differences
between
groups,
notably
that
gastrointestinal
symptoms
as
well
evaluations
same
significantly
more
frequent
variants,
headaches/dizziness
less
common
among
patients.
Livedo
reticularis
noted
four
patients,
exclusively
carriers.
Over
50%
Groups
1
2
carry
low-frequency
disease-associated
while
remaining
rare
unprecedently
digenic
i.e.,
coexistence
NLRP12,
which
either
low
frequency/rare.
Allele
frequencies
all
our
absent
lower
populations,
further
strengthening
evidence
susceptibility
SAID
phenotypes.
Conclusion
Our
comparative
shows
share
similar
clinical
phenotypes,
yet
there
them
regard
neurological
symptoms.
spectrum
high
genetic
variations
genes
can
contribute
individually
combination.
Neurobiology of Disease,
Год журнала:
2025,
Номер
unknown, С. 106861 - 106861
Опубликована: Март 1, 2025
Valosin-containing
protein
(VCP/p97)
is
a
ubiquitously
expressed
AAA+
ATPase
associated
with
numerous
protein-protein
interactions
and
critical
cellular
functions
including
degradation
clearance,
mitochondrial
homeostasis,
DNA
repair
replication,
cell
cycle
regulation,
endoplasmic
reticulum-associated
degradation,
lysosomal
autophagy
apoptosis.
Autosomal-dominant
missense
mutations
in
the
VCP
gene
may
result
VCP-associated
multisystem
proteinopathy
(VCP-MSP),
rare
degenerative
disorder
linked
to
heterogeneous
phenotypes
inclusion
body
myopathy
(IBM)
Paget's
disease
of
bone
(PDB)
frontotemporal
dementia
(FTD)
or
IBMPFD,
amyotrophic
lateral
sclerosis
(ALS),
Alzheimer's
(AD),
parkinsonism,
Charcot-Marie
Tooth
(CMT),
spastic
paraplegia.
The
complexity
VCP-MSP
makes
collaboration
among
stakeholders
essential
necessitates
multi-disciplinary
approach.
2024
International
Conference
was
hosted
at
Caltech
between
February
22
25.
Co-organized
by
Cure
Disease
Dr.
Tsui-Fen
Chou,
meeting
aimed
center
patient
as
research
partner,
harmonize
diverse
stakeholder
engagement,
bridge
gap
basic
clinical
neuroscience
it
relates
VCP-MSP.
Over
100
experts
attended,
ranging
from
scientists
clinicians
advocates.
Attendees
discussed
genetics
presentation,
molecular
mechanisms
underlying
disease,
therapeutic
approaches,
strategies
for
future
research.
conference
included
three
roundtable
discussions,
29
scientific
presentations,
32
posters,
nine
caregiver
closing
discussion
forum.
following
proceedings
summarize
these
sessions,
highlighting
both
identified
gaps
knowledge
significant
strides
made
towards
understanding
treating
diseases.